Emmaus Life Sciences (OTCQB: EMMA) reported net revenues of $6.3 million for the three months ended June 30, 2026, compared with $2.8 million in the prior-year period. The company recorded net income of $1.3 million, or $0.02 basic earnings per share, versus a net loss of $1.1 million a year earlier.
Revenue included recognition of part of an upfront payment and royalties under Emmaus' license and exclusive distribution agreement with NeoImmuneTech, effective May 15, 2026.
- Quarterly net revenue was $6.318 million, up from $2.817 million in the prior-year quarter.
- Operating expenses were $2.183 million, compared with $3.037 million a year earlier.
- Income from operations was $3.791 million, compared with an operating loss of $370,000.
- Cash and cash equivalents totaled $2.808 million as of June 30, 2026, compared with $2.127 million at December 31, 2025.
